Literature DB >> 11425157

Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline.

P Chetchotisakd1, W Chaowagul, P Mootsikapun, D Budhsarawong, B Thinkamrop.   

Abstract

This is a report of a randomized, open, labeled study of the maintenance treatment of melioidosis using a combination of ciprofloxacin and azithromycin (Regimen A) for 12 weeks versus a combination of cotrimoxazole and doxycycline (Regimen B) for 20 weeks. The study was conducted at two tertiary-care hospitals in northeast Thailand. A total 65 patients were enrolled, 36 and 29, respectively, between August 1997 and July 1998. Subjects were randomly allocated to each arm of the trial, resulting in 32 treated under Regimen A and 33 in B. The main outcome was a culture-proven relapse in melioidosis. There were more relapses under Regimen A at 22% (7 of 32) than in Regimen B, 3% (1 of 33). The 19% difference in the rates was significant (95% confidence interval [CI]: 3% to 34%; exact P-value = 0.027). Based on our data, a combination of cotrimoxazole and doxycycline treatment for 20 weeks should be given further consideration as the maintenance therapy of choice for melioidosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425157     DOI: 10.4269/ajtmh.2001.64.24

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  16 in total

1.  Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand.

Authors:  Vanaporn Wuthiekanun; Premjit Amornchai; Natnaree Saiprom; Narisara Chantratita; Wirongrong Chierakul; Gavin C K W Koh; Wipada Chaowagul; Nicholas P J Day; Direk Limmathurotsakul; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

2.  Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis.

Authors:  Wipada Chaowagul; Wirongrong Chierakul; Andrew J Simpson; Jennifer M Short; Kasia Stepniewska; Bina Maharjan; Adul Rajchanuvong; Duangkaew Busarawong; Direk Limmathurotsakul; Allen C Cheng; Vanaporn Wuthiekanun; Paul N Newton; Nicholas J White; Nicholas P J Day; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 3.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

4.  Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse.

Authors:  Bina Maharjan; Narisara Chantratita; Mongkol Vesaratchavest; Allen Cheng; Vanaporn Wuthiekanun; Wirongrong Chierakul; Wipada Chaowagul; Nicholas P J Day; Sharon J Peacock
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  Present and future therapeutic strategies for melioidosis and glanders.

Authors:  D Mark Estes; Steven W Dow; Herbert P Schweizer; Alfredo G Torres
Journal:  Expert Rev Anti Infect Ther       Date:  2010-03       Impact factor: 5.091

6.  Outcomes of patients with melioidosis treated with cotrimoxazole alone for eradication therapy.

Authors:  Sarunyou Chusri; Thanaporn Hortiwakul; Boonsri Charoenmak; Khachornsakdi Silpapojakul
Journal:  Am J Trop Med Hyg       Date:  2012-10-01       Impact factor: 2.345

7.  Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei.

Authors:  Sharon J Peacock; Herbert P Schweizer; David A B Dance; Theresa L Smith; Jay E Gee; Vanaporn Wuthiekanun; David DeShazer; Ivo Steinmetz; Patrick Tan; Bart J Currie
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

8.  Melioidosis with a Pericardial Effusion, which Relapsed as a Chest Wall Abscess: A Rare Presentation.

Authors:  Rashmi Teresa Mathai K; K Sundara Bhat; Mohammed Ashraf; Mayank Sarawag; Kumar K P
Journal:  J Clin Diagn Res       Date:  2013-04-01

9.  A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis.

Authors:  Thomas E J Chavas; Fang-Yi Su; Selvi Srinivasan; Debashish Roy; Brian Lee; Lara Lovelace-Macon; Guilhem F Rerolle; Elaine Limqueco; Shawn J Skerrett; Daniel M Ratner; T Eoin West; Patrick S Stayton
Journal:  J Control Release       Date:  2020-11-19       Impact factor: 9.776

10.  Antimicrobial drug-selection markers for Burkholderia pseudomallei and B. mallei.

Authors:  Herbert P Schweizer; Sharon J Peacock
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.